Welcome to our dedicated page for Ocuphire Pharma SEC filings (Ticker: OCUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocuphire Pharma’s SEC disclosures run hundreds of pages, packed with clinical-trial data, R&D accounting and complex licensing terms—details that can blur together when you just want to know whether APX3330 hit its study goals or how much cash runway remains. Our platform solves that problem by turning every Ocuphire Pharma SEC filing into plain-English insights the moment it hits EDGAR.
Need the numbers fast? The Ocuphire Pharma quarterly earnings report 10-Q filing is parsed for trial spend, partnership revenue and burn rate within seconds. Wondering if executives bought shares before new data? Check Ocuphire Pharma insider trading Form 4 transactions—we stream them in real time and flag patterns such as option exercises. Material trial updates? Our summaries of the latest Ocuphire Pharma 8-K material events explained show why the news matters without medical jargon.
Here’s what you can explore today:
- Ocuphire Pharma annual report 10-K simplified—AI highlights pipeline timelines, Ref-1 science and risk factors.
- Ocuphire Pharma Form 4 insider transactions real-time—track executive stock moves and set custom alerts.
- Ocuphire Pharma proxy statement executive compensation—compare stock-option grants to clinical milestones.
- Ocuphire Pharma earnings report filing analysis—view cash usage trends quarter over quarter.
From understanding Ocuphire Pharma SEC documents with AI to monitoring Ocuphire Pharma executive stock transactions Form 4, Stock Titan delivers every disclosure, summarized, searchable and always current. Spend minutes, not hours, getting the story behind OCUP’s drug-development journey.
Opus Genetics (Nasdaq:OCUP) filed a Form 8-K disclosing topline results from VEGA-3, its second pivotal Phase 3 trial of Phentolamine Ophthalmic Solution 0.75 % for presbyopia. Numerical efficacy and safety data were not included, but management deemed the readout material and will host a webcast on June 26, 2025 at 8:00 a.m. ET to discuss the findings and give a corporate update.
The filing reiterates prior guidance that cash on hand should fund operations into 2H FY 2026, suggesting no immediate financing need. Exhibit 99.1 contains the full press release; no new contracts, financings, or governance changes were reported. Forward-looking-statement disclaimers reference previously disclosed risk factors.
FAQ
What is the current stock price of Ocuphire Pharma (OCUP)?
What is the market cap of Ocuphire Pharma (OCUP)?
What is the core focus of Ocuphire Pharma Inc?
Which therapeutic areas does Ocuphire target?
How does Ocuphire generate revenue?
What distinguishes the lead drug candidate APX3330?
What role does Phentolamine Ophthalmic Solution play in the pipeline?
How does the management team contribute to the company's success?
How is Ocuphire positioned within the competitive landscape?
